DiaMedica Therapeutics Inc.

NASDAQ:DMAC

Biotechnology

Healthcare
$8.59 -0.17%

-$0.01 today

Market cap
$463.49M
Beta
1.00
P/E (TTM)
-8.8
EPS (TTM)
-$0.65
52W Low $3.48High $10.42

Volume 0.21M

Average 0.19M

DMAC Net Margin

Net income as a percentage of revenue, showing how much of each sales dollar becomes profit.

DiaMedica Therapeutics Inc.NASDAQ: DMAC

Net Margin · Q1 FY2026 · quarter ended Mar 2026

Net margin not reported for Q1 FY2026

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
—— QoQ
Last fiscal yearDec 2025
—— YoY
LTMMar 2026
—— YoY
Net Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3 years———
5 years——
10 years——

Net Margin history

Percent of revenue · from the income statement

No Net Margin data reported for this period type.

Net Margin vs competitors

How DMAC compares with its peers on the latest reported figures

DMAC Competitors Peer median
Net Margin for DMAC and competitors
Company Period LTM level YoY 3-year change
AKBAAkebia Therapeutics, Inc.LTM Mar 2026-8.8% +15.7 pp+30.0 pp
MAZEMaze Therapeutics, Inc.LTM Mar 2026-612.7% -643.7 pp—
BIOABioAge Labs, Inc.LTM Mar 2026-871.8% +4024.5 pp—
PROKProKidney Corp.LTM Mar 2026-8418.0% +13944.1 pp—
DNLIDenali Therapeutics Inc.LTM Jun 2026-14191.2% ——
DMACDiaMedica Therapeutics Inc.FY2025— ——
UNCYUnicycive Therapeutics, Inc.FY2025— ——
Peer median (excluding DMAC) -871.8%+2020.1 pp+30.0 pp

Competitors are the stored peer set for DMAC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue00000
Gross Profit00000
Gross Margin—————
Research & Development8.77M7.84M13.11M19.06M24.61M
Selling, General & Admin4.88M6.16M8.16M7.62M9.78M
Operating Expenses13.65M14M21.27M26.68M34.4M
Depreciation & Amortization24K25K30K39K43K
EBITDA(13.54M)(13.62M)(19.31M)(24.38M)(32.7M)
EBITDA Margin—————
Operating Income(13.65M)(14M)(21.27M)(26.68M)(34.4M)
Operating Margin—————
Interest Income0002.3M0
Interest Expense00000
Other Income / Expenses82K353K1.93M2.27M1.66M
Income Before Tax(13.56M)(13.65M)(19.34M)(24.41M)(32.74M)
Pre-Tax Margin—————
Income Tax Expense28K28K43K30K28K
Net Income(13.59M)(13.68M)(19.38M)(24.44M)(32.77M)
Net Margin—————
EPS (Basic)(0.65)(0.52)(0.60)(0.60)(0.70)
EPS (Diluted)(0.65)(0.52)(0.60)(0.60)(0.70)
Weighted Avg Shares20.77M26.44M32.57M40.4M46.98M
Weighted Avg Shares (Diluted)20.77M26.44M32.57M40.4M46.98M

DiaMedica Therapeutics Inc.

NASDAQ:DMAC

Intrinsic Alpha fair value

Locked

Current Price

$8.59

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.